Omadacycline vs. Moxifloxacin for Community-Acquired Pneumonia, 348 Patients

A single-center retrospective cohort study from the First Affiliated Hospital of Guangxi University of Science and Technology. The dataset compares the clinical effectiveness and safety of two antibiotics in 348 adult inpatients with community-acquired pneumonia between June 2022 and December 2024. It was authored by Tianliang Liu and shared under a CC-BY-4.0 license.

Use Cases

• Compare early clinical response rates between antibiotic treatments based on the primary efficacy endpoint.
• Analyze adverse event incidence for safety outcomes based on the described safety outcomes.
• Model the relationship between antibiotic choice and changes in inflammatory biomarkers based on WBC, CRP, and PCT data.
• Assess bacterial eradication rates as a secondary endpoint for treatment efficacy.

Strengths

• Includes 348 patient records with a defined cohort size of 170 and 178 per treatment group.
• Captures multiple clinical endpoints including early clinical response, overall response, bacterial eradication, and biomarker changes.
• Provides a real-world comparative perspective from a specific hospital setting.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is from a single center, which may limit generalizability.

Provenance

Source

First Affiliated Hospital of Guangxi University of Science and Technology

Collection Method

Single-center retrospective cohort study

Time Range

June 2022 to December 2024

Freshness

Last updated 2026-04-26 11:03:29; freshness should be verified.

Geography

Guangxi, China (inferred from hospital location)